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The recent research and technology development in medical genomics has raised
new issues that are profoundly different from those encountered in traditional clinical
research for which informed consent was developed. Global initiatives for international
collaboration and public participation in genomics research now face an increasing
demand for new forms of informed consent which reflect local contexts. This article
analyzes informed consent forms (ICFs) for genomic research formulated by four
selected research programs and institutes in East Asia – the Medical Genome Science
Program in Japan, Universiti Sains Malaysia Human Research Ethics Committee in
Malaysia, and the Taiwan Biobank and the Taipei Medical University- Joint Institutional
Review Board in Taiwan. The comparative text analysis highlights East Asian contexts
as distinct from other regions by identifying communicative and social functions of
consent forms. The communicative functions include re-contact options and offering
interactive support for research participants, and setting opportunities for family or
community engagement in the consent process. This implies that informed consent
cannot be validated solely with the completion of a consent form at the initial stage
of the research, and informed consent templates can facilitate interactions between
researchers and participants through (even before and after) the research process.
The social functions consist of informing participants of possible social risks that
include genetic discrimination, sample and data sharing, and highlighting the role of
ethics committees. Although international ethics harmonization and the subsequent
coordination of consent forms may be necessary to maintain the quality and consistency
of consent process for data-intensive international research, it is also worth paying more
attention to the local values and different settings that exist where research participants
are situated for research in medical genomics. More than simply tools to gain consent
from research participants, ICFs function rather as a device of social communication
between research communities and civic communities in liaison with intermediary agents
like ethics committees, genetic counselors, and public biobanks and databases.
Keywords: medical genomics, consent documents, group consent, family consent, community engagement
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INTRODUCTION
The rapid development of research and technology in medical
genomics over the last decade has raised new issues concerning
research design, sharing and future use of samples or data,
social risks, return of results, among others—all of which
are profoundly different from those encountered in traditional
clinical research for which informed consent was developed
(Beskow et al., 2001; Mascalzoni et al., 2008; McGuire et al.,
2008; Facio et al., 2012; Ayuso et al., 2013; Appelbaum et al.,
2014b; Khan et al., 2014; Grady, 2015). Global initiatives
for international collaboration and public participation in
genomic science and technology now face increasing demand for
international ethics harmonization to better assess the impact
and dynamics of global genome research in the requirements
of informed consent. As a result, research and policy experts
in East Asia have been quick to follow and embrace such
Western-oriented concepts and practices. This has created a
growing tension between these concepts and those that arise from
indigenous values, for which informed consent has been adapted
to local contexts (Hull et al., 2004; Mascalzoni et al., 2010; Rotimi
and Marshall, 2010; Henderson et al., 2014; Serepkaite et al., 2014;
Yoshizawa et al., 2014).
This article focuses on informed consent documents for
genomic research formulated for selected research programs and
institutes from Japan, Malaysia, and Taiwan. This selection is
seriously underrepresented even within their home countries.
Rather than attempt to make broad generalizations about the
situation in ‘East Asia,’ this article aims to explore the wide variety
of perspectives and practices related to informed consent in the
region. It finally extracts social and communicative functions
from the consent forms and discusses implications of how and
why these forms differ from the one that has been standardized
in the West.
This study used a qualitative method for text analysis of four
ICFs in three countries officially written in Japanese (Japan),
English and Malay (Malaysia) and Chinese (Taiwan). First, these
original documents were examined and summarized by section
in English by each of the authors (GY, THS, and C-HH). Second,
these English summaries were compared section-by-section
Abbreviations: EGC, Ethics and Governance Council of the Taiwan Biobank;
ELSI, ethical, legal and social implications; ERC, ethics review committee;
FERCAP, Forum for Ethical Review Committees in the Asian and Western
Pacific Region; GRC, Genomics Research Centre, Taiwan; GSP, Genome Science
Project, Japan; GWASs, genome-wide association studies; H3Africa, Human
Heredity and Health in Africa; HBMA, Human Biobank Management Act,
Taiwan; HSRA, Human Subjects Research Act, Taiwan; ICF, informed consent
form; ICGC, International Cancer Genome Consortium; IRB, institutional review
board; JAKOA, Department of Orang Asli Development, Malaysia; MEXT,
Ministry of Education, Culture, Sports, Science and Technology, Japan; MGSP,
Medical Genome Science Program, Japan; MMC, Malaysian Medical Council;
MREC-MOH, Medical Research Ethics Committee of Malaysian Ministry of
Health; MyHVP, Malaysian Node of the Human Variome Project; NERCIM,
National Ethics Review Committees in Malaysia; NHGRI, National Human
Genome Research Institute, United States; NHID, National Health Insurance
Database, Taiwan; PI, principal investigator; REC, research ethics committee;
TMC, The Malaysian Cohort; TMU, Taipei Medical University; ToMMo, Tohoku
Medical Megabank, Japan; USM, Universiti Sains Malaysia; USM-HREC, USM
Human Research Ethics Committee; USM-RCMO, USM Research Creativity and
Management Office; WHO, World Health Organization.
between the three cases and consent documents in other regions
including Europe, United States and Africa, supported by a vast
literature on informed consent. Third, key sections and words
for East Asian contexts were identified and categorized into two
thematic domains related to communication and society.
JAPAN
Human Genomics and Informed Consent
Process
In Japan many research institutions have now conducted human
genome studies and several organizations manage large-scale
biobanks including Biobank Japan (Triendl, 2003; Nakamura,
2007), the National Center Biobank Network (National Center
Biobank Network [NCBN], 2017), and the ToMMo (Matsui
and Tashiro, 2014). National databases include the Japanese
Genotype-phenotype Archive (JGA), which is conducted in
partnership with the National Bioscience Database Center
(NBDC) and the DNA Data Bank of Japan (DDBJ) (Kodama
et al., 2015), and the integrative Japanese Genome Variation
Database (iJGVD) as partly supported by the ToMMo Project
(Yamaguchi-Kabata et al., 2015). Human genome research is
regulated by the Ethical Guidelines for Human Genome/Gene
Analysis Research (‘Genome Guidelines’), which were established
by three government ministries in 2001 and have been revised
several times. The guidelines permit researchers to obtain broad
consent, whereby informed consent is granted not only for a
specific or defined project, but also extends to other genome
analyses or to other related medical research (Porter, 2009).
Initially in the 1990s, the Japanese legal concept of informed
consent was quite similar to the concept formulated in Western
law (Tejima, 2002), which has since been gradually and cautiously
accepted into medical practice (Leflar, 2001). Japan’s health care
policy is the first in the world to reimburse medical institutions
for the process of informed consent (Akabayashi and Fetters,
2000). At the same time, informed consent activities have become
more demanding and costly for professionals, allowing little time
for patients to consider the implications (Sakaguchi and Maeda,
2005; Fukuda et al., 2009).
Medical Genome Science Program
(MGSP)
Medical Genome Science Program is one of the largest genomics
projects in Japan and it has been funded by the MEXT since 1990.
This project acted in concert with the development of the Human
Genome Project, and it also gradually widened its research scope
to include plant and animal genomes and bioinformatics, as well
as the relationship between genome research and society (Itoh
and Kato, 2005). In the fifth stage of this project, the GSP started
to support MEXT-funded researchers in 2010. The MGSP is
one of four sub-activities in the GSP and has conducted new-
generation sequencing and associated bioinformatics analysis.
The Research Unit for the ELSI of Genomics based in the
GSP created an ICF for MGSP. The Unit drafted a template
by reviewing a number of consent documents established in
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the country and abroad and following Japanese government
guidelines and international norms and guidelines. The draft
template was refined over 2 months of close discussion and
communication between the Unit and executive researchers
in MGSP and GSP. This interactive process made genome
researchers aware of ethical implications of personal genome
research, and, on the other hand, enabled ELSI researchers to
incorporate pragmatic aspects of research into the design of the
ICF (Minari et al., 2014a).
The ICF of MGSP
The ICF template for 1st March 2013 consists of three parts:
the information sheet, the consent certificate and the withdrawal
of consent certificate. The information sheet is divided into
introductory remarks and 13 sections. The sheet enumerates
medical and scientific benefits as well as potential physical and
psychological risks of the research. To ease research participants’
anxiety and concern, it stresses that researchers can introduce
genetic counselors. There is an optional section for return of
results where the participant may be able to receive incidental
findings and the right not to know is also assured by checking the
box in the consent certificate. Note that the ICF explains that the
registration of research data to public databases enables a wider
range of researchers to use the data and contribute to advances
in medical science. There are two types of database access: those
open to the public; and those limited to qualified researchers
in aspects of scientific quality and managerial relevance to their
activities. The information sheet also states that intellectual
property rights as a result of genetic analysis shall belong to
researchers or organizations, but not to participants. The consent
certificate contains 13 boxes by section in the information sheet,
to be checked by each research participant if they understand the
content referred to. There are two indications of intention: one
is whether to receive the results of genetic analysis; and the other
is whether to agree with the storage of samples or information
longer than the initially scheduled period of research, in the case
of the extension or renewal of research. The research participant
or his/her legal representative should sign the certificate with the
date of signature. The withdrawal of consent certificate simply
states that the research participant will withdraw his or her
consent and requires their signature and the date of signature.
The end of the research may be extended or renewed with the
approval of ERCs. In the case of withdrawal, research participants
need to sign and submit the withdrawal of consent certificate (the
place of submission is open to users of the template), and then his
or her sample or information will be disposed of. However, the
information sheet adds a disclaimer that this may not be possible
once the information is published in academia or registered in
public databases.
Contextual Features
There are some specific features in the above ICF reflecting
academic, legal and social contexts in Japan. Because this
template is designed for the government-funded MGSP and the
government has been developing national genome databases and
biobanks, the value of the registration of data and samples to
public databases and biobanks is emphasized in two sections
of the information sheet. The term ‘disclosure of the results
of genetic analysis’ refers to terminology used in the revised
Genome Guidelines 2013, which follows the Protection of
Personal Information Act 2003 (Inoue and Tsuruyama, 2015).
In legal terms, researchers should disclose the results of genetic
analysis at request of the research participant, regardless of
whether the participant can fully understand the meaning of the
results. The Genome Guidelines and the subsequent ICF make
a practical compromise on the disclosure by stating that the
results can be disclosed only when proved to be beneficial for
medical treatment. In this sense, such disclosure can be called
‘returning’ the results, but the template prefers ‘disclosure’ as a
more legalistic term, which implies that the research results are
fundamentally attributed to researchers, and not to participants
(Masaki et al., 2014). Likewise, re-identifiable anonymization is
literally ‘linkable anonymization’ as a legal term representing
anonymized and coded information that is re-identifiable with
a separately stored table linking personal information and the
corresponding code.
The template makes researchers aware that individuals and
institutions are supporting medical genome research in several
ways, as the term ‘research participant’ is referred to literally
as ‘research cooperator’ in Japanese. First, for the function of
genetic counseling is described in the information sheet. Genetic
counselors are accredited by the Japanese Society for Genetic
Counseling and the Japan Society of Human Genetics since 2005
and there are 205 accredited counselors as of December 2016
(Yamamoto et al., 2009; Japanese Society for Genetic Counseling,
2017). Because most research institutes do not have a counseling
system and most studies may not require genetic counseling, the
counseling system is not specified in the template. Second, the
Genome Guidelines have been continually revised since 2001 and
researchers have increasingly complained about the complication
of its detailed instructions. To combat this tendency, the latest
version in 2013 has changed its strategy by giving leeway to
ERCs. Although this template was finalized before the publication
of the latest version of Genome Guidelines, the role of ERC
is noted repeatedly in the information sheet. Since 2012, the
Research Unit for the ELSI of Genomics has organized annual
meetings for members of ERCs on genomic research based in
different institutions across Japan. The aim is not to standardize
the process and the format of informed consent, but to facilitate
mutual learning by exchanging experiences and views on the
practical application of consent forms, such as broad consent,
informed assent, and multi-center collaborative studies.
MALAYSIA
Human Genomics and Informed Consent
Process
There are at least four major developments in Malaysia that
help to describe the country’s situation in biomedical research—
and especially in genomic science. First is the establishment of
TMC Project, initiated in 2005 by the Malaysian government
and based in Universiti Kebangsaan Malaysia. TMC has recruited
a total of at least 106,527 participants and each donated blood
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and urine (Jamal et al., 2015). Second is the MyHVP, which was
established in 2010 and based in Universiti Sains Malaysia. It
developed a specialized database of Malaysian genetic variations,
termed the MyHVP database (MyHVPDb) (Halim-Fikri et al.,
2015), which currently deposited 291,718 SNPs datasets of 103
Malay individuals (Nik Hassan et al., 2016). Third is support
from the Malaysian government on industry-sponsored clinical
trials, which has subsequently lead to increasing number of trials
where pharmacogenomic analysis was added as optional sub-
study (Economic Transformation Program–Healthcare Sector,
2010; Pharmaceutical Executive Editors, 2015; Clinical Research
Malaysia, 2016). Fourth is development in the area of medical
genetic services. Although clinical sequencing has not entered
routine clinical applications, clinical services, diagnostic services
and training programs for medical genetics, including that of
genetic counselors (Lee and Thong, 2013), are operational.
These are mainly catered by the three main public universities
(Universiti Malaya, Universiti Sains Malaysia, and Universiti
Kebangsaan Malaysia) and the national-referral Hospital Kuala
Lumpur, all located in Peninsular Malaysia.
Informed consent requirements have been well-described in
various guidelines adopted by Malaysian research institutions
(Abdul Rahman et al., 2011; Medical Research and Ethics
Committee [MREC], 2017). MMC Guidelines on Medical
Genetics and Genetic Services (Malaysian Medical Council
[MMC], 2006) suggested that a blanket informed consent is
the most efficient approach for stored genetic materials. This
is exactly following the WHO proposal on guiding the practice
(Wertz et al., 2003). In a broader context of informed consent
process in Malaysia, there is an observation of significant
medical paternalism between medical doctors and patients (Che
Ngah, 2005), although it should be careful to generalize this
to research practice. Another important observation is that,
in lawsuit cases, patients have shown a lack of understanding
of the consent documents, while medical doctors tend to
overlook the fact that signed consent forms as such do not
prove the patients’ understanding of and consent for the
issue in question. This becomes a relevant extension to the
practice of consent taking in genomic research, when one
considers the legal case of Havasupai Tribe vs. the Arizona
Board of Regents that ended in out-of-court settlement (Sterling,
2011).
Universiti Sains Malaysia Human
Research Ethics Committee
(USM-HREC)
Malaysian Medical Council [MMC] (2006) published its
guidelines on medical genetics and genetic services. This was
intended primarily to guide medical practitioners in their
practices with regards to medical genetics and genetic testing.
The guidelines also addressed research, banking of DNA
specimens and management of existing patient registries relating
to medical genetic services. The guidelines, however, do not
comprehensively and specifically address issues arising from the
latest genomic technologies which are increasingly in use by
Malaysian researchers. Realizing this lack, USM-HREC initiated
a formulation of guidelines and an informed consent template for
genomic studies in 2012.
This initiative was part of a broader context of quality and
capacity building initiatives mandated by the USM-RCMO to
USM-HREC which aims at obtaining international recognition
for its ethical review practices. USM-HREC adopted the
guidelines and the informed consent template by the end of
2012. The template was adapted from the United States NHGRI
informed consent template for genomic studies version 12.8.10
with their permission. In 2013, the newly adopted guidelines
and informed consent template were presented to the FERCAP
conference. In 2014, FERCAP awarded compliance recognition
to the ethical review practices of USM-HREC. USM-HREC
and the MREC-MOH subsequently started a discussion on the
initiation of a national network of ERCs. In March 2015, both
institutions organized the first meeting of the NERCIM in Kuala
Lumpur attended by ethics committees nation-wide where USM-
HREC’s guidelines and ICF template on genomic studies were
first introduced into the national audience. The 2nd NERCIM
meeting in October 2015 decided to make ethical review practices
of genetic and genomic studies as one of its focuses where USM-
HREC’s documents serve as a model for an ongoing national
harmonization. The following month, the guidelines and ICF
template were published (Sasongko et al., 2015).
The ICF of USM-HREC
The USM-HREC ICF template for genomic studies consists
of three parts: the research information, the research subject
information and consent form, and the research subject material
publication consent form. The research information part has
at least 12 sections and the latter two parts provide rooms for
signatures of research participants. By default, the USM-HREC
ICF encourages researchers to return or disclose individual
findings whenever the information benefits the participants.
Judgment about existence of such benefits lies with the researcher
under consultation with USM-HREC and mainly depends on
clinical significance, namely whether the information shows
sufficient analytic and clinical validity and potential health
implications either to individual research participants or his/her
family members. In case of incidental findings, however, the
ICF offers options if they would like to be informed. The in-
house guidelines related to the ICF (Sasongko et al., 2015)
stipulate that it is the responsibility of the researchers to provide
genetic counseling in order to deliver individual findings and to
factor in the genetic counseling cost, if any, into their research
budget. In most instances, this will be under the coverage of
the national health system. It is apparent that management of
findings in ICF of USM-HREC stands as a mode of providing
benefits and reward for participating in the research besides
ensuring that researchers would not keep clinically meaningful
individual genetic information from participants when it is
acquired during the course of the research. In this regard, the ICF
provides assurance to the participants that if it becomes available
through the research, their clinically meaningful individual
genetic information will be returned to them.
In addition, the USM-HREC ICF provides assurance to
participants about confidentiality through sections that explain
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protection of identifiable individual information and submission
to public database. It also states that withdrawal can be done
through destruction of the sample and data, although data
destruction would become impossible after it has been submitted
to public database. Besides, although researchers are basically
expected to destroy the samples after a certain period of time
(years) following completion of the study, they can offer an
option to participants to allow further storage by describing
possible future use of the sample. USM-HREC may or may not
require re-consent if researchers intend to pursue a new study
using the stored samples. Such exchange is further proposed
by notifying contact details of researchers’ and USM-HREC
secretariat, when participants would like to execute withdrawal
and if they have queries pertaining to research-related matters or
rights of participants.
Contextual Features
From the historical point of view, the model ICF was a
locally university-based initiative which was later taken up
at the national level. During the drafting process, emphasis
was given to sections concerning return of results, incidental
findings and sample/data storage. Due to the high costs of
genomic technologies, there have been growing concerns about
Malaysian researchers collaborating with researchers from more
established countries or with wider international research groups.
This has also inclined the researchers to share their data, re-
use the samples for future research and re-analyze the data
for different research objectives. While data sharing has been
generally regarded as spreading out the benefits on the use
of the data to a wider community, it has also been seen as
potentially sensitive to individual and community privacy where
the samples were taken. In Malaysia, it would be interesting to
see how the Personal Data Protection Act 2010 (Azmi, 2011)
affects formulation of consent documents. The Act makes an
exception on the condition that data processing is necessary
‘for medical purposes and is taken by’ healthcare professionals
[Section 40(1)] (Zawawi and Azmi, 2014). In this regard, this
exception requires valid medical reasons to be present. However,
as the consent provides a provision on the return of research
results through genetic counseling and the necessary medical
follow up, the Act may have an impact on the practice of
the consent implementation. Although doctors appear to be
aware of informed consent, practices which encourage patient
engagement in shared decision-making are rare (Ng et al., 2013).
While the ICF template mentions provisions regarding follow-
up testing and counseling sessions, it is noteworthy that not
all types of the required confirmatory testing must be carried
out within Malaysia. Researchers are expected, however, to assist
participants in looking for such testing especially if it is not
available in Malaysia.
Care for Ethnic Minorities and Family
Consent
It is of note that Malaysian aborigines, or Orang Asli in local
term, have been relatively frequent subjects of research, including
genetic research (Tuck-Po, 2011). JAKOA (Jabatan Kemajuan
Orang Asli) has requested that all research pertaining to Orang
Asli should put forward a prior proposal to this government
agency (JAKOA, 2017). There has been no stipulation pertaining
to the type of consent that should be used when it comes
to biomedical research. However, a recent report on Orang
Asli (Aghakhanian et al., 2015 and Hoh Boon Peng, personal
communication, 9 June 2016) employing a genomic methodology
revealed a practice whereby prior consultation was done to
the community elders before field visits to the community.
During the field visits, explanation on the study was given
en masse. Following the explanation, individuals interested to
participate would approach the research personnel where another
explanation would be given and individual signatures on the
consent document were collected. This study was approved by
JAKOA, Monash University (Malaysia)’s REC as well as MREC-
MOH.
USM Human Research Ethics Committee (USM/JEPEM/
15110477) and MREC-MOH (NMRR-15-2273-28140) have
recently approved a whole exome sequencing study protocol
which uses a family consent procedure. The study plans to
perform whole exome sequencing on family trios. The consent
process involves family discussion conducted by the research
personnel. Names of the participating family members will then
be listed on the signature page. An adult of legal age (normally
the father) who is also the participant will sign on behalf of
those whose names are listed. In addition, the USM-HREC
ICF recognizes the possibility of incidental findings of non-
paternity and researcher’s responsibility on the management of
the information. While it does not seem operational to put the
clause in the ICF (option of whether to be informed of such
findings), the research team decided to firstly perform the consent
process to the mother. Only when the mother indicates consent,
the process for the family consent ensues.
TAIWAN
Human Genomics and Informed Consent
Process
Taiwan’s genetics and genomics research is embedded in
the broader context of the development of biotechnology in
Taiwan. In order to upgrade the country’s capacity from a
manufacturing economy to a knowledge-based economy, since
1982, the government first listed biotech as one of the eight key
technologies to promote for Taiwan’s industry and placed life
sciences at the center of the state’s high-tech development plan
(Chiu, 2002). For nearly 30 years, the government nurtured life
sciences research by launching national programs and forming
institutes to provide an amicable environment to promote
biotech development. In 2003, the GRC was established by the
Academia Sinica, the highest academic institute in Taiwan, and
about 2 years’ later, the government launched the Biomedical
Technology Island Plan with the aim of further fostering Taiwan’s
genomics research and associated clinical trials. An important
sub-project under this grand umbrella scheme is to set up a large-
scale population biobank to support health and medical research
in Taiwan with particular attention to developing personalized
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medicine (Fan et al., 2008). Since the preparatory phases, one
of the main issues discussed among stakeholders has been how
to set up a suitable governance framework for national-scale
biobank practices that need to address legal and ethical concerns
of privacy and informed consent (Lin et al., 2011).
In 2010, the Legislative Yuan (Parliament) passed the draft
of the HBMA as a statutory basis for the establishment and
management of all types of biobanks in Taiwan (Fan and Lin,
2011). This legislation stipulates informed consent requirements
for sample collection and has been regarded as a basic regulatory
framework for designing consent template with regards to
biobank-related genetic research. On the other hand, the HSRA
in 2011 stipulates rules on obtaining consent as a legal safeguard
for the protection of human research subjects. In practice,
however, as the governance framework for ICFs on genomics is
rather fragmented, each hospital or medical research center relies
on its own in-house ICF approved by the IRB. This study takes
both the Taiwan Biobank ICF and the TMU- Joint IRB as cases
to illustrate informed consent practices for genomics research in
Taiwan.
The ICF of the Taiwan Biobank
The Taiwan Biobank, funded by the Ministry of Health and
Welfare, is a prospective long-term cohort which aims at
collecting 300,000 samples from healthy Taiwanese population
(200,000 samples) and patients (100,000 samples) in order to
study the causes of diseases, i.e., to find out the relationship
between genes, environment, and common complex diseases.
The pilot study was initiated in 2009, followed by the formal
collection of samples and data started in 2012. The Taiwan
Biobank ICF consists of three parts: the information sheet,
the advanced explanation sheet, and the consent sheet. The
information sheet provides a general introduction to the Taiwan
Biobank and the recruitment procedure for a participant to
further engage with the biobank at a sample collection site. The
advanced explanation sheet consists of 13 sections describing
matters related to biobanking activities in greater detail. Apart
from enumerating the purpose, rationale, and the competent
authority of the Taiwan Biobank in order to inform participants
about the general background about biobanking, this sheet
comprises several sections that are worth further discussion as
below.
First, the ICF of the Taiwan Biobank is carefully designed to
avoid therapeutic misconception, whereby participants attribute
therapeutic intent to research procedures (Appelbaum et al.,
1982). Such information delivery is important in the consent
form, on which the possible risks of taking part in biobank
research are required to be acknowledged fully to form an
accountable communication between biobank operators and
participants. On the Taiwan Biobank ICF, such risks include not
only individual ones of psychological and physical levels but also
social ones, such as data leakage and stigmatization even though
the ICF has explained that the research results will be published
as collective data with no individually identifiable information
released.
Second, the Taiwan Biobank ICF illustrated that a participant
can request by written declaration to cease providing samples
and data to the biobank, change the scope of the consented
use, and withdraw from participation of the biobank at any
time. It also outlines options for participants to decide if and
under what conditions that they would be willing to be re-
contacted by the biobank operator. Obtaining consent is treated
as a long-term practice rather than a once-time commitment
so that participants are given opportunities to change their
minds whenever they wish. Furthermore, according to the benefit
sharing requirement stipulated by Article 21 of HBMA in Taiwan,
any profits derived from commercial use and received by an
operator or the Biobank shall be given back to the human
population groups or specific population groups to which the
respective participants belong. This benefit sharing clause has
been integrated into the Taiwan Biobank ICF. Even though
the ICF articulates that biobank participants are not entitled to
claim any property rights derived from the biobank research as
such and that this property belongs to the research entity, it
nevertheless specifies that the participants are entitled to share
benefits according to the stipulations of HBMA. For this it
also states that participants can contact the biobank operator
or the EGC of the Taiwan Biobank about their complaints and
infringement concerns. The EGC functions not only as a contact
point, but also an independent review institution. As the biobank
requires broad consent, it is up to the scrutiny of the EGC to
further decide if an unspecified research purpose in the future will
be approved.
The ICF of TMU-Joint IRB on Genomics
Research
This ICF template consists of both an explanation sheet and a
consent sheet. The explanation part is further divided into 16
sections. Like the Taiwan Biobank ICF, it also requires PI to
illustrate the purpose of the study and suggests that the target
genes for research need to be described as specifically as possible
and identifies the potential physiological, psychological, and
social risks for participants to take part in the genomic research.
However, unlike biobank-related research, the ICF on genomics
studies requires PI to disclose identities of those who will access
to samples and data and if the samples will be transferred to other
research entities outside of Taiwan (and if so, it shall also indicate
the related personnel). As for the secondary use of samples and
data, the ICF allows participants an option to further decide
if they would be willing to have their samples to be used for
different biomedical research purposes (in such cases, another
ICF is required to be signed) or if instead they would prefer their
samples to be disposed of after the completion of the current
research.
In terms of research feedback, participants are allowed to
decide if they would like PI to inform them of research results
or provide related medical information and counseling services.
If not, the ICF suggests that PI needs to state clearly that the
individual research results will not be provided even though
participants are still welcome to access to the research results
that have been published as an aggregated data. Furthermore,
the ICF also allows participants to decide how they would like
their samples and data to be handled if later on they decide to
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withdraw from the study. Such options for participants include
the following—either samples or data can be used for the current
study unless otherwise indicated, or samples and data will have
to be disposed of immediately when participants withdraw from
the current research. According to the ICF of the TMU-Joint IRB,
there is a requirement for PI to notify participants of any derived
rights and benefits, including commercial benefits according to
the rules of HSRA. Moreover, the ICF explains the protection of
genetic information through anonymization and the aggregation
of personal data. However, it does not exclude the possibility
of releasing the data to a competent authority for investigation
according to law, and that is quite different from the ICF used
for biobank-related research stipulated by HBMA. The ICF also
provides contact information of its IRB for participants who need
further information.
Contextual Features
The above case study demonstrates that the informed consent
practices for genomic studies in Taiwan vary widely. Apart from
the biobank-related study and the Taiwan Biobank, which are
mainly regulated by HBMA, research centers and hospitals rely
on their in-house ICF templates that follow HSRA to obtain
consent for genomics research. One example of this variety lies
in whether participants’ data and information can be released
and used for non-research investigation purposes. Such use
of the data outside of the original purpose of research has
been explicitly prohibited by HBMA (Article 20), which applies
to all biobank-related research, but it may be permitted by
an in-house ICF template for genomic studies as the TMU
case demonstrates. Efforts toward standardization of various
consent forms for genomics research have not been successfully
implemented even though Taiwan is a member of FERCAP
network. Thus even though the TMU case could not be regarded
as a representative, it demonstrates an example of diverse consent
practices in Taiwan. Furthermore, while genetic counseling
services have developed in recent years (Chien et al., 2013),
whether each service is required to return research results—
especially regarding incidental findings—or whether they have to
provide genetic counseling may also vary by consent form and
the nature of the biomedical research in question.
Group Consent
Except for the individual consent, there is also a statutory
obligation for collective consent when research subjects involve
Taiwanese aborigines. According to the Taiwan Aboriginal Basic
Law (Article 21) and HSRA (Article 15), when the research
subject involves aboriginal people, which are approximately of
2% of the whole 23 million populations in Taiwan, consultations
need to be carried out for obtaining collective consent from the
aboriginal groups. Such group consent is required not only for
biomedical research itself but also for publication of research
results about Taiwanese aborigines. To date there have been
debates and discussions on drafting implementing rules of group
consent that are to be proposed from the Council of Indigenous
People – the competent authority of aboriginal matters in the
Cabinet (Executive Yuan). The practice of informed consent in
Taiwan has demonstrated that individual consent may not be
sufficient for genomics research when the research subjects are
ethnic minority groups, and that the publication of research
results may have unfavorable effects—such as stigmatization—
for these particular groups (Ho, 2012; Lin and Liao, 2012;
Munsterhjelm, 2014).
COMPARATIVE ANALYSIS
This analysis not only compares the above ICFs, but also
examines ICFs from other regional contexts. In Europe, the
European Union (EU) Clinical Trial Directive (2001/20/EC)
defines informed consent and contains guidance on how to
draft a consent form. With respect to human genomics, there
is a study of 14 consent form documents from 2004 to 2010
used in European GWASs projects (Boddington et al., 2011).
A more recent study examines consent forms of Genomics
England’s 100,000 Genomes Project (Chow-White et al., 2015).
H3Africa Working Group on Ethics developed a set of guidelines
for informed consent on genomic research in 2013, and a
recent study analyzed informed consent documents for 13 of
the 19 H3Africa projects (Munung et al., 2016). There seem
no comparable review studies in the United States, but the
informed consent elements are required by the Common Rule
(45 CFR 46, Subpart A) and sample documents are provided by
NHGRI. International documents include an ICF template for
the 1000 Genomes Project (2016) and the ICGC model consent
brochure (International Cancer Genome Consortium [ICGC],
2010). These references are qualitatively analyzed and compared
with the above documents on a section or clause basis by taking
into account different policy, social and cultural contexts. The
comparative text analysis identifies communicative and social
functions of the ICF, which may highlight East Asian contexts as
distinct from other regions (Table 1).
Communicative Functions
Improvement of participants’ literacy is a critical challenge to
achieving valid consent (Raich et al., 2001; de Vries et al.,
2011), which also requires the improvement of readability and
content in ICFs (Jefford and Moore, 2008; Nair and Ibrahim,
2015). Readability of the informed consent document has been
a major discussion topic in research and practice, but the above
case study demonstrates three other communicative functions of
ICFs which have been relatively overlooked in early literature –
namely, re-contact options, interactive support, and family or
community engagement.
First, each ICF sets several options for participants regarding
the future use of data and samples, how to withdraw from
research and whether they wish to be re-contacted with regard
to incidental findings. Re-contact options on incidental findings
are explicitly stated in Malaysian USM-HREC and suggested
in Japanese MGSP. This is a staged consent model, in which
participants are given time for consideration in order to come
to understanding decisions (Bunnik et al., 2013), particularly in
the ICF that they receive information about incidental findings
later when reported (Appelbaum et al., 2014a). In the United
States, the American College of Medical Genetics and Genomics
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TABLE 1 | Statement on social and communicative functions in the ICF.
Communicative
functions
MGSP, Japan USM-HREC, Malaysia Taiwan biobank TMU-Joint IRB, Taiwan
Re-contact options Incidental findings (Section 5) Incidental findings (Section 7);
Future use of specimens
(Section 12)
Follow-up (Section 7) Future use of specimens
(Section 8); Change of the
scope (Section 14)
Interactive support Reference to genetic
counselors (Section 11)
Independent opinion on the
research and the rights of
participants (Section 9)
Appeal about participant’s
complaints and infringement
concerns (Section 13)
Contact information of the
IRB (Section 16)
Family or community
engagement
n/s Family consent allowed;
Community consultation
required for Malaysian Orang
Asli
Group consent for Taiwanese aborigines would be required
(under consultation for its implementing rules)
Social functions
Genetic discrimination Social discrimination (Section 4) Distress to participants and
their families (Section 5)
Risk of stigmatization
(Section 10)
Impact on social interests in
education, employment and
medical care (Section 4)
Sample and data sharing Public storage of samples and
data for medical advancement
(Sections 7, 8)
Submission to a nationally or
internationally shared database
as public data release
(Section 11)
Data and information can be
linked to national databases
with the approval from the EGC
(Section 9)
n/s
Role of ethics committee At the extension of research
duration and initiation of new
research (Section 9)
Independent opinion; Contact
point (Section 9)
Independent review institution;
Contact point (Section 13)
Independent review
institution; Contact point
(Section 15)
(ACMG) recommended re-contact policy settings for informed
consent on new knowledge about the significance of particular
results of genome/exome sequencing (ACMG Board of Directors,
2013). Re-contact options for future use of data and samples
are set in the ICF of TMU-Joint IRB in Taiwan, as sometimes
stated in European and African context (Boddington et al., 2011;
Munung et al., 2016). In contrast, re-contact options in Taiwan
Biobank are mainly set for follow-up purposes. A Japanese
study on biobank research participants reveals that post-consent
communication serves as a trust building experience (Watanabe
et al., 2011), so re-contact options may give another opportunity
to facilitate meaningful communication between researchers and
participants.
Second, the above forms offer counseling or consultation
support for research participants, following government
guidelines in Japan or the practice of the plurality of opinions in
Malaysia. In Taiwan, such genetic counseling service does not
appear on the Taiwan Biobank consent form, but participants
can appeal to the biobank or the EGC about their complaints and
infringement concerns. While there appear no similar statements
on counseling or consultation support in other continents, a
Canadian study reveals that the majority of consent documents
did not mention genetic counseling (Egalite et al., 2014).
Such intermediary services become crucial as the boundary
between research and treatment become increasingly blurred
and therapeutic misconception can be fueled by participants and
researchers (Halverson and Ross, 2012; Tupasela et al., 2017).
Third, informed consent forms function as a communication
tool not merely between researchers and participants. In the
process of informed consent on clinical decision-making, family
members also have a role for decision support and anxiety
reduction in Japan (Hattori et al., 1991; Ruhnke et al., 2000;
Sullivan, 2015), while in Taiwan they act as liaisons for
information and advocates in the physician-patient relationship
under the legal framework (Lin et al., 2013). With a growing need
for family centric initiatives for obtaining consent in genomics
research (Minari et al., 2014b), East Asian countries may be
quick to absorb a new model of informed consent, as the above
Malaysian ICF suggests. Underlining communicative functions
of consent forms also allows researchers to collaborate with
others in a public domain and to empower their community
(Chokshi et al., 2007). In Taiwan, HSRA stipulates group
consent requirements when Taiwanese aborigines are recruited
as research subjects in genetics and genomics research. This
reflexively nudges participants to pay attention to the potential
benefits and risks of genetic analysis for their ethnic communities.
It is too simplistic to say that ethical decision-making in East
Asian countries is more family- or community-centered than
Western countries (Akabayashi and Slingsby, 2006; Chen et al.,
2013), but it is nevertheless true that family and community
considerations are important in clinical practice and research in
East Asia (Pratt et al., 2014). Like in Africa (Ramsay et al., 2014),
community approval would not supersede individual informed
consent in East Asia. As a pre-research community engagement
process is recommendable to develop consent form for genetic
research (Marsh et al., 2010; Brief et al., 2012), systematic
documentation of community engagement would become a key
part in the consent process in Malaysia (Allotey et al., 2014).
ICFs thus illuminate the relevance of communication between
researchers and participants through research projects and the
value of communities engaged with participants (Skinner et al.,
2015).
All the above three communicative functions imply that
informed consent cannot be validated solely with the completion
of a consent form at the initial stage of the research, and informed
consent templates can facilitate interactions between researchers
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and participants through (even before and after) the research
process.
Social Functions
Informed consent forms can also shed light on social aspects
of genomics research. There are at least three social functions
identified from the above cases in comparison with documents in
other regions; genetic discrimination, sample and data sharing,
and the role of ethics committee (i.e., ERC, IRB, or REC).
First, while many research participants are afraid of the risks of
genetic discrimination through participation in genetics research
(Hamvas et al., 2004), most East Asian countries do not have
legal safeguards against genetic discrimination (Joly et al., 2010;
Yoon et al., 2011; Otlowski et al., 2012). However, as in the
case of a Japanese genetic cohort study (Matsui et al., 2008),
most research participants may wish to have future disclosure of
individual risks. Against this backdrop, each of the above ICFs
tries to deliberately mitigate participants’ anxiety about possible
social risks not followed by current legislations. Similarly,
H3Africa Guidelines include risks of group discrimination and
stigmatization as suggested elements for genomic studies.
Second, the consent template for MGSP in Japan encourages
researchers to register their data and samples to national
public databases and biobanks. In Malaysia, researchers have
come under pressures in global research collaborations, for
which sharing data via national or international databases is
motivated as in the USM-HREC consent form. In Taiwan, even
though the feedback of incidental findings is not allowed in the
practice of Taiwan Biobank, according to Article 21 of HBMA,
participants are entitled to share the benefits from biobank
research. Co-funded by the National Institute of Health and the
Wellcome Trust, all H3Africa consent documents are required
to comply with the American Common Rule and thus make
mention of data sharing (H3Africa, 2013; Wright et al., 2013).
In effect, most of them included a statement about data and
sample sharing by reason of progression of research, best practice,
or the right thing to do (Munung et al., 2016). On balance, a
variety of guidelines and sample ICFs collected from all over
the world reflect different stances in sample and data sharing
between (1) Europe and North America, which have established
internationally recognized and well-networked databases and
biobanks; (2) Far East Asian countries, which have promoted
state-sponsored databases and biobanks as national catching-
up strategies (Kuo, 2011); and (3) South East Asia and Africa,
which have begun to provide genome data and samples for global
research and practice. In Africa, however, clear concerns about
requesting consent for the wide sharing of data and samples are
reported (Ramsay et al., 2014).
Third, in the United States, most chairs of IRBs at centers
conducting genomic studies do not know what is required for
local boards regarding informed consent (Simon et al., 2011),
while a number of different domestic IRB collaborations are
in place (Barchi et al., 2014). In South Asia, ERCs become
incapable of protecting human subjects against competing social
and national interests (Simpson et al., 2015). Going against the
tendency of more emphasis on the importance of data in making
and informing decisions in ethics committees (Sugarman, 2004),
consent forms may need to be carefully designed to reflect social
and national interests as well as local values placed by wider
engagement so that the ethics committees can address and review
issues more promptly and effectively. There are also differences
in how to use consent documents between ERCs (Edwards et al.,
2007). In developing countries, written consent was documented
in most cases, but was more likely to be obtained by researchers
and participants with higher literacy (Hyder and Wali, 2006).
Under the circumstances, African experience suggests that IRB
members should be trained on all phases of research methodology
including informed consent (Falusi et al., 2007; Kaas et al., 2007).
In Europe, harmonization between RECs has been driven initially
by the Clinical Trials Directive (Hedgecoe et al., 2006), and also
recently promoted by the European Forum for Good Clinical
Practice (EFGCP) (Davies et al., 2009; Cairoli et al., 2012).
Given no such directives or common rules regionally adopted
throughout a continent except FERCAP, ERCs in East Asia are
likely to have considerable discretion about how to document
and review consent forms. In this sense, clear statements on
the role of ERC in consent documents, as demonstrated in the
above case study, would construct more dynamic and responsible
relationship between the research participant and the ERC.
CONCLUSION
The section-by-section text analysis of different ICFs for a variety
of genomic studies in East Asia reveals critical features that reflect
local contexts as distinct from consent documents formulated
in other regions. In terms of communicative aspects, East Asian
consent forms are keen to set plural options and contact points
and in some cases facilitate family or community engagement
for the research participant. From a social perspective, first, there
are statements on potential social risks for research participants
in the above ICFs. Because most East Asian countries do not
have legal safeguards against genetic discrimination, the above
consent forms are deliberately designed to warn participants
about such social risks. Second, most of the above consent
forms impress upon researchers and participants the relevance
of data and samples, as well as the benefit of sharing via
public databases or biobanks. Third, statements on the role of
ethics committees suggest dynamic and responsible relationships
between the research participant and the committee so that
East Asian ethics committees are likely to have considerable
discretion about documentation and review of ICFs. Thus
consent forms stand not just as a legal contract between
individual researchers and participants but rather as a device
for social communication between research communities and
civic communities in liaison with intermediary agents like
ethics committees, genetic counselors, and public biobanks and
databases. Although international ethics harmonization and the
subsequent coordination of consent forms may be necessary to
maintain the quality and consistency of the consent process for
data-intensive international research (Dove et al., 2016), it is also
worth paying more attention to the local values and different
settings of the locations where medical genomic research is
conducted.
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